Advances and Limitations of Antibody Drug Conjugates for Cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the ADC is partly based on the stability and successful cleavage of selective linkers for the delivery of the payload. The current research focuses on overcoming intrinsic shortcomings that impact the successful development of ADCs. This review summarizes marketed and recently approved ADCs, compares the features of various linker designs and payloads commonly used for ADC conjugation, and outlines cancer specific ADCs that are currently in late-stage clinical trials for the treatment of cancer. In addition, it addresses the issues surrounding drug resistance and strategies to overcome resistance, the impact of a narrow therapeutic index on treatment outcomes, the impact of drug–antibody ratio (DAR) and hydrophobicity on ADC clearance and protein aggregation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403 · cited 1×
“On the other hand, hydrophilic payloads of the ADC lead to a bystander effect [81].”
BackgroundStrategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054 · cited 1×
“Hypoxia is one of the many causes of therapy resistance [80].”
BackgroundAntibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930 · cited 2×
“Acid cleavable linkers cannot be used to conjugate highly cytotoxic drugs [4,42,68,69].”
BackgroundAntibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304 · cited 7×
“PBD is selective as it can only bind to double stranded DNA and not single stranded DNA [96,97].”
BackgroundInfluentialErickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246 · cited 1×
“The difference between the two ADCs is that T-DM1 employed a non-cleavable thioether liker whereas lorvotuzumab mertansine employed a cleavable disulfide linker [102].”
BackgroundMinor groove binder antibody conjugates employing a water soluble β-glucuronide linker
Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B., & Senter, P. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.071 · Cited by 59
Wang, Y., Fan, S., Xiao, D., Xie, F., Li, W., Zhong, W., & Zhou, X. (2019) · Cancers · doi:10.3390/cancers11070957 · Cited by 50
Cited by
Antibody–drug conjugates: Recent advances in payloads
Wang, Z., Li, H., Gou, L., Li, W., & Wang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.015 · Cited by 264
“ADCs have become one of the fastest-developing drug classes in oncology in recent years, because of their lower side effects, broader treatment applications, and higher therapeutic index 4,5 .”
BackgroundAhn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01544 · Cited by 244
“12 More recently, EVOKE-01, evaluating sacituzumab govitecan (a TROP2-directed antibody – drug conjugate with a plasma-labile linker 30 ) in a similar NSCLC population, failed to meet its primary end point of improved OS compared with docetaxel, with no improvement in PFS or ORR compared with…”
Antibody-Drug Conjugates in Prostate Cancer: Where Are we?
Mjaess, G., Aoun, F., Rassy, E., Diamand, R., Albisinni, S., & Roumeguère, T. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.07.009 · Cited by 22
Metadata
- Authors
- Mckertish, C., & Kayser, V.
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2021-07-23
- Volume
- 9
- Issue
- 8
- Pages
- 872
- ISSN
- 2227-9059 (ISSN-L)
- OpenAlex
- W3185894875
- Cited by
- 161
- References
- 8
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances and Limitations of Antibody Drug Conjugates for Cancer. https://app.cochat.ai/papers/10.3390/biomedicines9080872
- The paper
- Mckertish, C., & Kayser, V. (2021). Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines. https://doi.org/10.3390/biomedicines9080872
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.